Comment
doi: 10.1056/NEJMc1808567.
Pembrolizumab plus Chemotherapy in Lung Cancer
Affiliations
- PMID: 30211498
- DOI: 10.1056/NEJMc1808567
Item in Clipboard
Comment
Pembrolizumab plus Chemotherapy in Lung Cancer
N Engl J Med.
.
No abstract available
Comment in
-
Pembrolizumab plus Chemotherapy in Lung Cancer.N Engl J Med. 2018 Sep 13;379(11):e18. doi: 10.1056/NEJMc1808567. N Engl J Med. 2018. PMID: 30207917 No abstract available.
Comment on
-
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16. N Engl J Med. 2018. PMID: 29658856 Clinical Trial.
Similar articles
-
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.Cancer. 2020 Nov 15;126(22):4867-4877. doi: 10.1002/cncr.33142. Epub 2020 Sep 11. Cancer. 2020. PMID: 32914866 Free PMC article.
-
Pembrolizumab plus Chemotherapy in Lung Cancer.N Engl J Med. 2018 Sep 13;379(11):e18. doi: 10.1056/NEJMc1808567. N Engl J Med. 2018. PMID: 30211501 No abstract available.
-
Pembrolizumab plus Chemotherapy in Lung Cancer.N Engl J Med. 2018 Sep 13;379(11):e18. doi: 10.1056/NEJMc1808567. N Engl J Med. 2018. PMID: 30211499 No abstract available.
-
Pembrolizumab for the first-line treatment of non-small cell lung cancer.Expert Opin Biol Ther. 2018 Oct;18(10):1015-1021. doi: 10.1080/14712598.2018.1522300. Epub 2018 Sep 19. Expert Opin Biol Ther. 2018. PMID: 30207786 Review.
-
Pembrolizumab for choroidal metastases from non-small cell lung cancer: a case report and literature review.Hum Vaccin Immunother. 2021 Aug 3;17(8):2626-2629. doi: 10.1080/21645515.2021.1885282. Epub 2021 Mar 26. Hum Vaccin Immunother. 2021. PMID: 33769211 Free PMC article. Review.
Cited by
-
Evaluation of Overall Survival by Restricted Mean Survival Time of Advanced Biliary Tract Cancer treated with Immunotherapy: A Systematic Review and Meta-Analysis.Cancers (Basel). 2024 May 30;16(11):2077. doi: 10.3390/cancers16112077. Cancers (Basel). 2024. PMID: 38893196 Free PMC article. Review.
-
Clinical and pharmacoeconomic impact of subgroup analysis in onco-hematological patients.Support Care Cancer. 2022 May;30(5):3761-3772. doi: 10.1007/s00520-022-06823-y. Epub 2022 Jan 13. Support Care Cancer. 2022. PMID: 35028720 Review.
-
Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.BMC Cancer. 2020 Jun 18;20(1):571. doi: 10.1186/s12885-020-07057-z. BMC Cancer. 2020. PMID: 32552717 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
